Cardiff Oncology (CRDF) vs Tenaya Therapeutics (TNYA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Cardiff Oncology (CRDF) has outperformed Tenaya Therapeutics (TNYA) over the past year, losing 58.0% versus a loss of 76.7%. Over five years, CRDF leads with a -84.8% price change compared with -98.5% for TNYA. Cardiff Oncology is the larger company by market cap ($66.3 million vs $65.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRDF | TNYA |
|---|---|---|
| Share price | $0.8528 | $0.2866 |
| Market cap | $66.34M | $65.32M |
| 1-day change | -4.46% | -3.99% |
| YTD return | -69.65% | -59.75% |
| 1-year return | -57.99% | -76.70% |
| 5-year return | -84.80% | -98.50% |
| EPS (TTM) | $-0.54 | $-0.48 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $593.00K | — |
| Revenue growth (YoY) | -13.18% | — |
| Net income (latest FY) | $-45.85M | $-90.60M |
| Operating margin | -8256.32% | — |
| Net margin | -7732.04% | — |
| 52-week high | $3.31 | $1.46 |
| 52-week low | $0.71 | $0.28 |
| Distance from 52-week high | -74.24% | -80.37% |
| Analyst consensus | none | none |
| Avg. price target upside | +581.29% | +1016.54% |
| Average volume | 1.01M | 2.96M |
| Shares outstanding | 77.80M | 227.93M |
| Employees | 30 | 70 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CRDF has outperformed TNYA by 18.7 percentage points over the past year.
About Cardiff Oncology
CRDF stock →Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 30 employees
About Tenaya Therapeutics
TNYA stock →Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 70 employees
CRDF vs TNYA FAQ
Which is bigger, Cardiff Oncology or Tenaya Therapeutics?
Cardiff Oncology (CRDF) is larger, with a market capitalization of $66.34M compared with $65.32M for Tenaya Therapeutics (TNYA).
Which stock has performed better over the past year, CRDF or TNYA?
CRDF returned -57.99% over the past 12 months, compared with -76.70% for TNYA (price return, excluding dividends). Past performance does not predict future results.
Are Cardiff Oncology and Tenaya Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.